Skip to content

Summit Therapeutics SMMT Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax

Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax at other companies

Merck & Co. logo
Merck & Co.MRK
Exelixis logo
ExelixisEXEL
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
Gilead Sciences logo
Gilead SciencesGILD
Biogen logo
BiogenBIIB
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN

Other financials

Income statement

See full
Revenue-
Operating income-$65.6M-81.2%
Net income-$189.4M-201%
EPS (diluted)-$0.24-167%

Balance sheet

See full
Cash & equivalents$8.2M+7.2%
Total debt$20.0M+211%
Total equity$545.9M+58.5%
Total assets$647.9M+68.8%

Cash flow

See full
Operating cash flow-$122.3M-99.9%
CapEx$245.0K-41.9%
Free cash flow-$122.5M-99.0%

Valuation

See full
Market cap$10.67B+3.3%
Enterprise value$10.68B+3.4%

Profitability

See full
Operating margin-268,266.8%-272,316pp
Net margin-271,685%-275,966pp
FCF margin-5,931.6%+4,730pp

Returns & leverage

See full
Return on equity-271%-1,725pp
Debt / equity0.0×
Current ratio7.4×-3.2×

Where this comes from

Reported directly by Summit Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax.

The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Summit Therapeutics's debt securities, available-for-sale, accumulated gross unrealized loss, before tax.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Summit Therapeutics's debt securities, available-for-sale, accumulated gross unrealized loss, before tax?
Summit Therapeutics (SMMT) reported debt securities, available-for-sale, accumulated gross unrealized loss, before tax of $4K in Q1 2026.
How has Summit Therapeutics's debt securities, available-for-sale, accumulated gross unrealized loss, before tax changed year-over-year?
Summit Therapeutics's debt securities, available-for-sale, accumulated gross unrealized loss, before tax decreased by 87.9% year-over-year, from $33K to $4K.